Overview
Ilaria Tanasi practices in Verona, Italy. Ms. Tanasi is rated as an Experienced expert by MediFind in the treatment of Hereditary Alpha-Tryptasemia. Her top areas of expertise are Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Leukemia, and Acute Lymphoblastic Leukemia (ALL).
Her clinical research consists of co-authoring 35 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Hereditary Alpha-Tryptasemia.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Mast Cell Activation Syndrome (MCAS)Ms. Tanasi isDistinguished. Learn about Mast Cell Activation Syndrome (MCAS).
- Systemic MastocytosisMs. Tanasi isDistinguished. Learn about Systemic Mastocytosis.
- Advanced
- Acute Lymphoblastic Leukemia (ALL)
- LeukemiaMs. Tanasi isAdvanced. Learn about Leukemia.
- Experienced
- Acute Myeloid Leukemia (AML)Ms. Tanasi isExperienced. Learn about Acute Myeloid Leukemia (AML).
- AnaphylaxisMs. Tanasi isExperienced. Learn about Anaphylaxis.
- AnemiaMs. Tanasi isExperienced. Learn about Anemia.
- B-Cell LymphomaMs. Tanasi isExperienced. Learn about B-Cell Lymphoma.
- Chronic Myelogenous Leukemia (CML)Ms. Tanasi isExperienced. Learn about Chronic Myelogenous Leukemia (CML).
- Diffuse Large B-Cell Lymphoma (DLBCL)Ms. Tanasi isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).